| John K. A. Prendergast |
John K. A. Prendergast was the founder of Avigen, Inc. (founded in 1992) where he served as the Lead Director from 1992 to 2009. He is also the founder of Palatin Technologies, Inc. (founded in 1986) where he currently holds the position of Non-Executive Chairman. Dr. Prendergast is also the founder of Antyra, Inc., Nejo, Inc...His current job(s) include being the Executive Chairman at Recce Pharmaceuticals Ltd. since 2018, a Director at Ingenex, Inc., the Lead Independent Director at Elusys Therapeutics, Inc., the Lead Independent Director at Scorpius Holdings, Inc. since 2016, and the President of SummerCloud Bay, Inc. since 1993. His former job(s) include being the Chairman & Chief Executive Officer of AVAX Technologies, Inc. from 1996 to 2013, the Lead Director of MediciNova, Inc. from 2004 to 2011, and the Managing Director of Castle Group Ltd. from 1991 to 1997. He also held positions as a Managing Director at Paramount Capital Investments LLC and as a Director at Osaka Exchange, Inc. In terms of education, Dr. Prendergast holds an MBA from Harvard University and has graduate and doctorate degrees from The University of New South Wales. |
| Michael B. Raizman |
Michael B. Raizman is associated with Palatin Technologies, Inc. as the Chief Medical Officer since 2021. He is also an Associate Professor at Tufts University School of Medicine. |
| Stephen A. Slusher |
Stephen A. Slusher is currently the Chief Legal Officer at Palatin Technologies, Inc. He has a graduate degree from The University of New Mexico and an undergraduate degree from St. John's College. |
| John Dodd |
John Dodd currently works at Palatin Technologies, Inc., as Senior Vice President-Preclinical Development. Dr. Dodd received his graduate degree from The Pennsylvania State University. |
| Stephen T. Wills |
Stephen T. Wills currently works at Gamida Cell Ltd., as Independent Director from 2019, MediWound Ltd., as Independent Director from 2022, Amryt Pharma Plc, as Non-Executive Director from 2019, Palatin Technologies, Inc., as COO, CFO, Secretary, Treasurer & Executive VP from 2011, Sanofi-Synthélabo Ltd., as Head-Worldwide Marketing & Cardiovascular, The American Institute of Certified Public Accountants, as Member, New Jersey Society of Certified Public Accountants, as Member, Pennsylvania Institute of Certified Public Accountants, as Member, and Cactus Acquisition Corp. 1 Ltd., as Chief Financial Officer from 2024. Mr. Wills also formerly worked at Derma Sciences, Inc., as Executive Chairman & Chief Executive Officer from 2015 to 2017, Derma Sciences Canada, Inc., as Chairman & Chief Executive Officer from 2015 to 2017, U.S. Helicopter Corp., as Chairman from 2006 to 2010, Caliper Corp., as Chairman from 2016 to 2019, Hun School of Princeton, Inc., as Chairman from 2018 to 2023, Miami International Holdings, Inc., as Director, Miami International Securities Exchange LLC, as Director, Amryt Pharma Holdings Ltd., as Non-Executive Director from 2019 to 2023, Biogen, Inc., as Vice President-International Business, Golomb Wills & Co. CPA, as President & Chief Operating Officer from 1991 to 2000, Wills, Owens & Baker Pc, as President & Chief Operating Officer from 1991 to 2000, and Cactus Acquisition Corp. 1 Ltd., as Chief Financial Officer from 2021 to 2024. Mr. Wills received his graduate degree in 1994 from Temple University (Pennsylvania) and undergraduate degree in 1979 from West Chester University of Pennsylvania. |
| Carl Spana |
Carl Spana is the founder of Palatin Technologies, Inc., which was founded in 1986. He currently holds the position of President, Chief Executive Officer & Director at Palatin Technologies, Inc. He is also currently the President & Director at RhoMed, Inc. In the past, Dr. Spana has held positions as a Director at AVAX Technologies, Inc., a Director at Microlin Bio, Inc., a Research Associate at Bristol Myers Squibb Co., and a Vice President at Paramount BioCapital Asset Management, Inc., Castle Group Ltd., and Paramount Capital Investments LLC. Dr. Spana has an undergraduate degree from Rutgers State University of New Jersey and a doctorate degree from The Johns Hopkins University. |
| Joseph Stanley Hull |
Joseph Stanley Hull is an Independent Director at Palatin Technologies, Inc. since 2005. He was previously a Senior Vice President-Pharmaceuticals at GlaxoSmithKline LLC from 1987 to 2010. Before that, he was a VP & Director-Therapeutic Development at Glaxo Wellcome, Inc. Mr. Hull completed his undergraduate degree at The University of North Carolina at Greensboro. |
| Alan W. Dunton |
Alan W. Dunton founded Danerius LLC in 2006, where he worked as Principal from 2006 to 2015. Dr. Dunton also currently works at Palatin Technologies, Inc., as Independent Director from 2011, Oragenics, Inc., as Independent Director from 2011, ActivBiotics, Inc., as Director from 2007, and various other companies. Dr. Dunton also formerly worked at Metaphore Pharmaceuticals, Inc., as President & Chief Executive Officer from 2003 to 2006, Janssen-Cilag International NV, as Chairman, EpiCept Corp., as Non-Executive Chairman from 2012 to 2013, and various other companies. Dr. Dunton received his undergraduate degree from State University of New York at Buffalo and doctorate degree in 1980 from New York University School of Medicine. |
| Robert K. deVeer |
Robert K. deVeer is currently an Independent Director at Palatin Technologies, Inc., an Advisor at Trelys LLC, and the President of deVeer Capital LLC. He previously served as an Independent Director at Solutia, Inc. from 2008 to 2012. He was also the Managing Director & Head-Industrial Group at Lehman Brothers Private Equity Group from 1995 to 1996. Additionally, he held positions as the Head-Finance at Credit Suisse Private Equity LLC from 1973 to 1994 and as the Head-Project Finance & Industrials at CS First Boston Pacific, Inc. in 1995. Mr. deVeer has a degree in undergraduate studies from Yale University and an MBA from Stanford Graduate School of Business. |
| Anthony M. Manning |
Anthony M. Manning is the founder of Institute For Biomedical Entrepreneurship, Inc. He currently holds the position of Independent Director at Palatin Technologies, Inc. since 2017, Independent Director at Monte Rosa Therapeutics, Inc. since 2023, and Principal at Manning Bio Worldwide LLC. Previously, he worked as the Head of Research at Celgene Corp., Vice President & Head of Autoimmune Diseases Research at Biogen, Inc. from 2007 to 2011, Principal at Signal Pharmaceuticals, Inc., Vice President & Global Head of Inflammation at Roche Pharmaceuticals, Inc. from 2002 to 2007, Senior Vice President of Research at Momenta Pharmaceuticals, Inc., SVP of Research & Preclinical Development at Aileron Therapeutics, Inc. from 2011 to 2013, and Vice President at Pharmacia Corp. from 2000 to 2002. He obtained his doctorate degree from the University of Otago in 1990. |
| Arlene M. Morris |
Arlene M. Morris is currently the Chief Executive Officer at Willow Advisors LLC since 2015. She is also the Chairman at TC Biopharm (Holdings) Plc since 2022. Additionally, she holds the position of Independent Director at Palatin Technologies, Inc. since 2015, Viveve, Inc. since 2016, Cogent Biosciences, Inc. since 2019, Viridian Therapeutics, Inc. since 2018, and Director at Charleston Animal Society since 2022. Previously, Ms. Morris served as the President, Chief Executive Officer & Director at Syndax Pharmaceuticals, Inc. from 2012 to 2015. She held the same positions at Affymax, Inc. from 2003 to 2011 and Clearview Projects, Inc. from 2002 to 2004. She was also the Chairman at Nuon Therapeutics, Inc. and an Independent Director at MediciNova, Inc. from 2011 to 2013. Ms. Morris served as a Director at Biodel, Inc. from 2015 to 2016 and the Biotechnology Innovation Organization from 2006 to 2011. She was a Director at the Humane Society of Silicon Valley from 2009 to 2011 and the Medical University of South Carolina Foundation. She also served as an Independent Director at Dimension Therapeutics, Inc. from 2015 to 2018, Neovacs SA from 2011 to 2020, Neovacs, Inc. from 2011 to 2021, and Viveve Medical, Inc. from 2016 to 2022. Ms. Morris held the position of Senior Vice President-Business Development at Coulter Pharmaceuticals, Inc. from 1996 to 2001, Scios, Inc. from 1993 to 1996, and Johnson & Johnson from 1977 to 1993. Ms. Morris completed her undergraduate studies at Carlow College and Western New England University. |
